Novartis confident in safety and efficacy of its seasonal influenza vaccines produced in Italy
25 October 2012 | By Novartis
Confidence in the safety and efficacy of seasonal influenza vaccines...
List view / Grid view
25 October 2012 | By Novartis
Confidence in the safety and efficacy of seasonal influenza vaccines...
12 October 2012 | By Novartis
Gilenya® the first once-daily oral therapy...
10 October 2012 | By Novartis
New data to be presented...
1 October 2012 | By Novartis
Seebri® Breezhaler® approved...
5 September 2012 | By Novartis
New data for Lucentis®...
3 September 2012 | By Novartis
Further data from the COPD clinical trial programs...
30 August 2012 | By Novartis
SPARK met its primary endpoint...
29 August 2012 | By Novartis
Novartis welcomed its annual International Biotechnology Leadership Camp...
28 August 2012 | By Novartis
Novartis received approval today from the European Commission for Jakavi®...
26 August 2012 | By Novartis
Novartis announced results from the Phase II PARAMOUNT study...
15 August 2012 | By Novartis
Results of two Phase III studies...
6 August 2012 | By Novartis
Collaboration to study CAR technology...
30 July 2012 | By Novartis
The EC has approved Afinitor®...
20 July 2012 | By Novartis
The US FDA has approved Afinitor® tablets...
22 June 2012 | By Novartis
CHMP has adopted a positive opinion for Seebri® Breezhaler®...